Belite Bio (BLTE) Free Cash Flow (2020 - 2025)
Belite Bio (BLTE) posted quarterly Free Cash Flow of -$10.4 million for Q4 2025, down 114.88% year-over-year from $69.8 million in Q4 2024, and down 114.88% quarter-over-quarter from -$4.8 million in Q4 2024.
Powered by 
Analysis
Belite Bio (BLTE) Free Cash Flow (2020 - 2025) Analysis & Trends
Belite Bio's Free Cash Flow history runs 2 years deep, the most recent figure standing at -$10.4 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 114.88% year-over-year to -$10.4 million; the TTM figure through Mar 2026 stood at -$10.4 million (down 114.88% YoY), while the FY2025 annual figure was -$37.1 million, down 26.27% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$10.4 million, down from -$4.8 million in the prior quarter.
- The five-year high for Free Cash Flow was -$4.8 million in Q4 2024, with the low at -$10.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Belite Bio | 6.25 Bn | 6.25 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2024 | -4.60 Mn |
| Dec 31, 2022 | -11.06 Mn |
| Dec 31, 2021 | -7.40 Mn |
| Dec 31, 2020 | -4.42 Mn |